(Q37826430)

23 August 2017

1 reference

title

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer (English)

1 reference

23 August 2017

1 reference

Ewan Jd Robson

1

1 reference

23 August 2017

Prafull Ghatage

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

6 January 2011

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

20

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

297-304

1 reference

Global cancer statistics, 2002

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Beyond chemotherapy: targeted therapies in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Angiopoietin: a TIE(d) balance in tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Angiopoietins 3 and 4: diverging gene counterparts in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Angiopoietins in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Antiangiogenic drugs in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Current status on biologic therapies in the treatment of epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Assessing tumor angiogenesis using macromolecular MR imaging contrast media.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.549125

10.1517/13543784.2011.549125

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference